| Ranking | Study title | Summary |
|---|---|---|
|
Top European Recruiter |
OPTIMA |
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis |
|
Top UK Recruiter |
BNT122 01 |
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection |
|
Top UK Recruiter |
CONCORDE |
A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non-small cell lung cancer |
|
Top UK Recruiter |
MK-1308A-008 |
A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer |
|
Top UK Recruiter |
Ariel |
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) |
|
Top UK Recruiter |
RAPPER |
Radiogenomics: Assessment of Polymorphisms for Predicting the effects of Radiotherapy |
|
Top UK Recruiter |
I-Prehab |
Inclusive prehab (I-Prehab) to address inequity in cancer outcomes: mixed-methods evaluation research |
|
Top UK Recruiter |
CA209-76K
|
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma |
|
Top UK Recruiter |
Hidden 2 |
Hospital Deep Vein Thrombosis Detection Study in Cancer Patients Receiving Palliative Care |
|
Top UK Recruiter |
PEARL |
PET based adaptive radiotherapy in locally advanced HPV positive oropharyngeal cancer |
|
Top UK Recruiter |
PACIFIC 8 |
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy |
|
Top UK Recruiter |
INTRINSIC |
Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer A Phase II trial of Durvalumab (MEDI 4736) in Combination with Extended Neoadjuvant Regimens in Rectal Cancer |
|
Top UK Recruiter |
SERENITY |
Barriers and facilitators to deprescribing antithrombotic therapy in advanced cancer patients: A qualitative interview study of patients’, companions’ and clinicians’ experiences and perspectives |
|
Top UK Recruiter |
ARISTOCRAT |
A randomised controlled phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma |
|
2nd Highest UK Recruiter |
PARTNER |
Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA. |
|
2nd Highest UK Recruiter |
Genmab GCT1015-05 |
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC_ in combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer |
|
2nd Highest UK Recruiter |
SCOPE 2 |
A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET) |
|
2nd Highest UK Recruiter |
CORINTH |
Phase 1 B/II trial of checkpoint inhibitor (Pembrolizumab an anti PD-1 Antibody) plus standard IMRT in HPV induced Stage III Squamous Cell Carcinoma (SCC) of anus |
|
2nd Highest UK Recruiter |
TROPION 02 |
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer |
|
2nd Highest UK Recruiter |
Phoenix |
A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer Version: 1.0 |
|
Joint 2nd Highest UK Recruiter |
SCANCELL (The Scope Study) |
A Phase 2, Multicenter, Open-Label Study of SCIB1 in Patients with Advanced Unresectable Melanoma Receiving Pembrolizumab |
|
Joint 2nd Highest UK Recruiter |
Cypides |
Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer |
|
3rd Highest UK Recruiter |
PLATFORM |
Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial |
|
3rd Highest UK Recruiter |
LIBRETTO-531 |
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer |
|
2nd Highest UK Recruiter |
TROPION 03 |
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy |
|
3rd Highest UK Recruiter |
TRITON 3 |
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency |
|
3rd Highest UK Recruiter |
VALTIVE1 |
A non-randomised, observational, biomarker study to determine the clinical value of measuring plasma Tie2 concentrations in patients with ovarian cancer who are receiving bevacizumab |
|
3rd Highest UK Recruiter |
Aurora |
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial |
|
3rd Highest UK Recruiter |
Cardiac Care |
A multicentre prospective randomised open-label blinded end-point controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in breast cancer patients receiving anthracycline adjuvant therapy. |
|
4th Highest UK Recruiter |
PARADIGM 2 |
OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newly diagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies |
|
4th Highest UK Recruiter |
InPACT |
International Penile Advanced Cancer Trial |
|
4th Highest UK Recruiter |
SPECTA |
Screening Cancer Patients for Efficient Clinical Trial Access |
|
4th Highest UK Recruiter |
Glioblastoma |
Improving treatment of glioblastoma, 1.0 |
|
Joint 4th Highest UK Recruiter |
NET-02 |
A non-interventional, multicenter, multiple cohort study investigating the outcomes and safety of atezolizumab under real-world conditions in patients treated in routine clinical practice |
|
Joint 4th Highest UK Recruiter |
AVANZAR |
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations |
|
Joint 4th Highest UK Recruiter |
BO42864 (A.K.A BLU-667-2303 & AcceleRET Lung) |
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer |
|
5th Highest UK Recruiter |
E²-RADIatE |
OligoCare: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients |
|
Joint 5th Highest UK Recruiter |
CAPItello-281 |
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency |